DYADIC (DIL) ++ Enzyme für Bioethanol aus Biomasse + Abengoa investiert 10 Mill. USD ++ - 500 Beiträge pro Seite

[bossi1]

....ENZYME und mehr

Dyadic is applying its proprietary enabling biotechnologies for multi-billion dollar markets in industrial enzymes, biofuels and biotherapeutics....dann sollte man das hier weiter verfolgen. Ich bin bei Abengoa in Spanien investiert und dadurch auf diesen Wert gestoßen. Abengoa hat am 25.10.2006 2,136,752 Aktien von DYADIC für 10 Mill.USD gekauft.

DYADIC Homepage
http://www.dyadic-group.com/wt/dyad/news

--------------

Dyadic Enters Into Research and Development Agreement with Abengoa Bioenergy in the Area of Cellulosic Ethanol Production

Abengoa Bioenergy to Purchase $10 Million of Dyadic Common Stock

Jupiter, Fla

October 27, 2006


Dyadic International, Inc. (AMEX: DIL), a biotechnology company, today announced that it has signed a three-year research and development (R&D) agreement and a stock purchase agreement with Abengoa Bioenergy R&D, Inc. (ABRD), an Abengoa Bioenergy Company focusing on research and development. Under the terms of the purchase agreement, Abengoa Bioenergy has agreed to invest $10 million in Dyadic, for which it will be issued 2,136,752 shares of Dyadic Common Stock at $4.68 per share (based on the closing sales price on October 25, 2006, as reported on the American Stock Exchange). The closing of the sale of the common shares is subject to approval of the listing of the shares by the American Stock Exchange and other customary closing conditions. After the closing, under certain circumstances, additional securities may be issuable to ABRD. Cowen and Company, LLC, acted as an advisor to Dyadic.

Dyadic will use the proceeds from this private sale to fund its R&D obligations under the R&D agreement, which has as its objective the development of a cost-effective enzyme production system for commercial application in Abengoa Bioenergy’s bioethanol (cellulosic ethanol) production process. The R&D agreement, which does not become effective until the private sale closes, calls upon Dyadic to use its proprietary technologies to develop one or more enzyme mixture manufacturing systems customized to ABRD’s proprietary biomass substrates. The R&D agreement contemplates that Dyadic will perform both foundational research of general application to the cellulosic ethanol field and specific applications research for the achievement of the goals of ABRD’s program. Under the terms of the R&D agreement, if Dyadic successfully develops one or more enzyme manufacturing systems for Abengoa Bioenergy, Dyadic may be entitled to receive license fees, technology transfer fees and royalties on ethanol sales. Other financial terms were not disclosed.

“Abengoa Bioenergy is considered to be the second largest ethanol producer in the world and a leader in the fields of both corn-derived and cellulose-derived ethanol production. We are extremely pleased to partner with Abengoa Bioenergy to leverage Dyadic’s patented C1 platform enzyme technology to enable commercial development of biomass derived ethanol,” said Glenn E. Nedwin, Ph.D., Chief Science Officer for Dyadic.

“We recognized that Dyadic’s enzyme technology, especially in the field of cellulosic ethanol, is state-of-the-art,” said Gerson Santos-Leon, R&D Director of Abengoa Bioenergy. “Abengoa Bioenergy is looking forward to working with Dyadic in the development of large-scale enzyme production systems and manufacturing processes for use in the production of abundant low cost fermentable sugars from biomass, with initial focus on cellulosic ethanol production.”

“We are very excited to enter into this partnership with Abengoa Bioenergy, a recognized leader in the field of cellulosic ethanol, and are also pleased to welcome ABRD as a strategic investor, research collaborator and Dyadic shareholder,” commented Dyadic’s President and CEO, Mark Emalfarb. “Abengoa Bioenergy is a visionary company and an important first partner for Dyadic for its Biorefineries Business. Additional partners will stand to benefit not only from access to Dyadic’s technologies specific to their area of interest but also from the core technology development program that is fundamental to efficient production of ethanol, other biofuels, polymers and other chemicals from biomass, thereby reducing our dependence on foreign oil.”

Javier Salgado, Abengoa Bioenergy´s President & CEO, added: “Dyadic is recognized as a leader in innovation and technology in the enzymes production field. This investment and the R&D collaboration with Dyadic represent a key building block in the Abengoa Bioenergy Biomass Program, particularly in the area of specialized enzymes.”

Pursuant to the parties’ purchase agreement, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued at closing, as well as the additional shares, if any, issuable after the closing.

The securities offered in the private sale were not registered under the Securities Act of 1933, as amended (the "Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws.

About Dyadic
Dyadic International, Inc. is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper and animal feed industries.

About Abengoa Bioenergy
Abengoa Bioenergy is considered to be the second largest ethanol producer in the world with production facilities located in Europe and the USA. Abengoa Bioenergy is one of the five business units of Abengoa, S.A. (ABG:MC), a technology company that applies innovative solutions for sustainable development in the infrastructures, environment and energy sectors. Abengoa, S.A. is a listed company on the Madrid Stock Exchange with 2005 revenues of approximately two billion euros, and is present in more that seventy countries where it operates with its five business units; Solar, Bioenergy, Environmental Services, Information Technologies, and Industrial Engineering and Construction

http://www.abengoa.com/

[bossi1]

Beyond corn: Ethanol's next generation
Scientists seek cheap, plentiful energy alternatives

By Michael Oneal
Tribune staff reporter

October 13, 2006 - WEST LAFAYETTE, Ind. -- Sitting in a cluttered, windowless office here surrounded by pictures of her three grandchildren, Nancy W.Y. Ho did her best on a recent afternoon to show why everything you thought you knew about ethanol is wrong.

It's not just about distilling auto fuel from corn, explained the 71-year-old molecular biologist from China. It's about weaning America from its self-destructive oil habit by tapping the energy in everything else that grows--and rots--all around us.

Ho has spent the better part of a career at Purdue University figuring out how to rejigger the DNA of a simple form of brewer's yeast by cloning a gene nobody else had thought to clone.

Now, if you stir her creation into a beaker filled with the sugars derived from throwaway organic materials like wheat straw, switch grass, orange peels, even municipal garbage, it will gradually convert most of them into high-octane auto fuel.

"Everybody knows that [corn] is not enough," Ho said. "We have to use all the resources we can."

As the combines roll across fields throughout the Corn Belt this harvest season, the debate over ethanol has never been hotter. On Wednesday, President Bush reiterated his support for ethanol funding at a conference on renewable energy in St. Louis. But critics bemoaning the folly of hefty government subsidies over the years continue to insist that ethanol is a wasteful, extravagant boondoggle.

Producing ethanol from corn in any real volume, they say, threatens the food supply, uses too much land and creates a litany of messy environmental issues. The U.S. burns through 140 billion gallons of gasoline a year. Replacing that with ethanol is pipe dream.

Changing the game

For a growing number of scientists, entrepreneurs and policymakers, however, the constant grumbling about corn ethanol entirely misses the point. While they don't disagree that the corn-based fuel has major limitations, they insist that obsessing over them is like disparaging first-generation personal computers for being slow and unwieldy.

Breakthroughs in genetic and industrial engineering, they insist, are changing the game. Not only is technology making corn ethanol more efficient, but researchers like Ho are making striking progress toward tapping what scientists call cellulosic biomass, the vast store of non-food plant matter that grows and renews itself daily.

If they succeed, many experts believe, cellulosic ethanol could be a plentiful, cheap and easily renewable oil alternative, with few of the negatives that plague the corn-based variety.

"It's the holy grail ... if you can make it work," said John Felmy, chief economist at the American Petroleum Institute.

The question is, can you really make it work?

On a sun-baked plateau in Golden, Colo., scientists at the Department of Energy's National Renewable Energy Laboratory have been working on that question for three decades. James McMillan, a top biochemical engineer at the lab, said the outlook has never been brighter.

One measure of that promise is the unprecedented investment pouring into the industry. Most recently, British transportation magnate Richard Branson has pledged $3 billion over 10 years for research into cellulosic ethanol and other biofuels. BP PLC, the world's second-largest oil company, has earmarked $1 billion to be split evenly between research and venture financing.

Even Bush has surprised his allies in the oil business by pushing the Energy Department to dole out more than $400 million in fresh funding for ethanol-related research and development.

"This country's got to use its talent and its wealth to get us off oil," Bush said on Wednesday. "I believe, and Congress agrees, that the proper use of tax credits will help stimulate a new industry that will help our economy and help us with national security."

Strolling through a state-of-the-art test facility in Golden devoted to distilling cellulosic ethanol, however, McMillan makes it clear that the future isn't here yet. The building is a welter of pipes, tanks and valves, and as he points out the different phases of the production process he notes that crucial improvements must be made to each if cellulosic ethanol is ever going to truly compete with oil.

Looming stubbornly in front of researchers is a masterpiece of evolution: the rigid cell walls that give plants their strength and resiliency. Developed over the eons, these walls allow a slender stalk of prairie grass to bend like a ballerina in the wind yet snap back to attention to fend off cold, heat and pestilence. They help explain why a field of corn can grow over a man's head in a matter of a few short months.

The problem is, breaking down those walls is like robbing a bank. While the starch in corn kernels gives up its energy-packed sugars easily, the sugars in plant cell walls are locked into winding structures of complex carbohydrates designed to give plants backbone and protection.

Getting at those sugars in an efficient way is the secret to tapping the energy potential of cellulosic biomass, McMillan explained. Researchers long have known how to do it in the lab. But nobody has yet proved it can be done profitably in a commercial-scale plant. To get there, some of the best minds in science are creating such wonders as fungi that are genetically modified to spit out vats of powerful enzymes, and transgenic prairie grasses that are bursting with energy yet engineered to break down more easily.

"This is transformative technology," said Sharlene Weatherwax, a program manager in the U.S. Energy Department's Office of Science. "It's pretty daunting."

What's even more daunting is the economic challenge. Estimates are unreliable, but at the moment most experts believe it is probably more expensive to produce a gallon of cellulosic ethanol than an equivalent volume of gasoline. The comparison is even less favorable if you consider that ethanol produces about a third fewer miles per gallon than gasoline in typical engines. Fighting through these hurdles is attractive when oil is at $70 a barrel, but less so as the price falls. Most experts agree that corn ethanol is cost competitive when the price per barrel of oil is $40 or higher.

Despite using cheaper feedstocks to make cellulosic ethanol, the capital outlay to build more complicated plants drives up costs. McMillan said that it runs from $2.50 to $4 per gallon of capacity to build a typical cellulosic-ethanol plant. That compares with $1 to $1.50 for a corn-ethanol plant.

Plowing ahead

None of this has stopped pioneering companies like Canada's Iogen Corp. or Spain's Abengoa Bioenergy from plowing ahead with plans to build what the ethanol industry calls biorefineries. The Department of Energy has allocated $160 million to help develop three cellulosic demonstration plants. Iogen, Abengoa and several others have applied.

These ventures are highly risky but exactly what the industry needs, said Steven Koonin, oil giant BP's chief scientist. As the technology matures, he said, somebody like Iogen needs to build a plant, power through the learning curve and solve the inevitable problems that crop up.

Jeff Passmore, Iogen's executive vice president of development, is confident his company is well on the way to cracking the cellulosic-ethanol problem. But he also concedes that developing a new plant at commercial scale represents more a voyage of discovery than a hard and fast business plan.

"The more you know," Passmore said, "the more you know you don't know."

The reason Passmore and others persevere is that the knowledge gap has been closing faster over the past several years than it has for the past three decades. Breakthroughs in biotechnology are producing gains in productivity that are steadily driving costs out of each phase of the cellulosic production process.

Iogen, for instance, is using Ho's genetically modified yeast organism to address a major competitive handicap. As much as 40 percent of the sugars contained in typical forms of cellulosic biomass are of a type that normal yeast won't metabolize. Consequently, the process starts out at a 40 percent efficiency disadvantage to corn ethanol, which produces sugars that are 100 percent convertible with normal yeast.

The goal of Ho's cloning exercise was to tweak the yeast into converting both kinds of sugars almost simultaneously, boosting fermenting efficiency substantially. The result is a major step forward, but Ho and her colleague, Miroslav Sedlak, hope to do better. They are toiling to make the organism more efficient.

"With industry," Ho said. "if its not efficient, nobody is going to use it."

For Chicago native Mark Emalfarb, who founded a Florida biotech company called Dyadic International Inc., the hard work originally involved stonewashed jeans.

In the early 1990s, he ferreted out a fungus discovered on the floor of a lakeside forest on Russia's Pacific Coast. Known as chrysosporium lucknowense, or C1, the organism produced the kinds of cotton-fading enzymes that allowed denim companies to take the stones out of the stonewash process.

What the enzymes actually did was break down the plant cell walls in cotton, the same metabolic process needed to release the sugars for cellulosic ethanol. Unfortunately, the fungus produced the enzymes only in tiny amounts. So Emalfarb hired a team of scientists to bombard C1 with ultraviolet radiation until it one day mutated into a "biofactory" that could spit out enzymes in commercial quantities.

"We don't even know how the hell it happened," Emalfarb said. "It was serendipitous."

Dyadic has since introduced C1 into the same kind of high-speed robotic screening process that pharmaceutical companies use to ferret out new drugs. That means splicing different sequences of DNA into thousands of individual C1 fungi at a time and seeing what enzymes each one produces as a result of its newly altered genome.

The goal is to find enzymes, or "cocktails" of enzymes, that are particularly adept at breaking down various kinds of plant matter. Once researchers find the right enzyme recipe for breaking down, say, wood chips, they can genetically alter C1 to produce that particular blend of enzymes in quantity, something evolution might take eons to do.

"It's like Charles Darwin on steroids," said Dyadic Vice President Sasha Bondar.

Ancient discovery

Mike Himmel, a principal scientist at the National Renewable Energy Laboratory, said this sort of eye-popping research is happening across many branches of science and engineering. He recently attended a conference in Aspen, Colo., where a plant geneticist gave a paper on primordial plants that had low levels of a substance called lignin and high levels of sugar. Because the plants grew in swamps, they hadn't yet evolved the defensive structures that lignin offers modern plants.

"It occurred to me that what people are really going to be doing here is redefining modern plants to look more like ancient plants," Himmel said.

Richard Hamilton, CEO of a California plant genetics company called Ceres Inc., is trying to do exactly that. By analyzing 12,000 switch-grass genes and characterizing the genetic variation associated with each one, Ceres has created a trait database that it hopes to use to create the most effective varieties of "energy crops."

Already, Ceres and its partner, the Samuel Roberts Noble Foundation, are marking genes to increase the effectiveness of conventional breeding. But they are working to perfect cloning strategies that turn on or turn off specific genes that regulate traits like yield, drought tolerance or plant structure.

Using the fruit fly of the plant world, a rapid-growing species called arabidopsis thaliana, the company clones hundreds of transgenic plants a week. The goal is to find novel traits--plants that might break down more easily in a biorefinery, for instance, or varieties that produce more energy per acre.

That would address what Hamilton termed "the tyranny of distance," a major cost issue for would-be producers of cellulosic ethanol. If a refinery needs tons of biomass to produce fuel, he said, "by the end of the year you're driving your truck a long way to get that wheat or corn stover." If Ceres could develop a higher-yielding plant, travel distance, and cost, would shrink accordingly, he said.

When asked how long it will take to transform some of these ideas into reality, Hamilton and others in the industry tend to shrug.

"Trying to predict technology trends is a fool's game," he said. "I wish I could put my finger on just one bottleneck. But it doesn't work that way."

On the other hand, most experts in the field agree that focus is a powerful thing, especially when the federal government starts to put real resources behind an idea. As evidence that giant steps can be made in a hurry, McMillan points to two enzyme companies called Novozymes Inc. and Genencor International. They took approximately $40 million in Department of Energy funding over five years and knocked the cost of the latest enzymes down from about $5.50 per gallon to about 20 cents.

The Department of Energy has set a goal of supplying 30 percent of the nation's need for transportation fuels with ethanol by 2030, a tall order given that ethanol currently supplies about 3.6 percent of the 140 billion gallons of gasoline we consume each year.

But even some unlikely sources say the need for oil alternatives is severe enough to drive a major transformation.

"We're not going to replace oil in the next 20 years, but the resource is finite," said BP chief scientist Koonin. "The world is going to need more diverse hydrocarbons going forward. ... For many reasons it seems that this is the right thing at the right time. It's very exciting."

----------

[e-mail]

- - -

Not all ethanol created equal

The vast majority of U.S.-made ethanol uses corn as its primary ingredient, but some researchers say that ethanol made from cellulosic biomass, or plant waste, is a better alternative.

U.S. ETHANOL PRODUCTION

For fuel, scale in billions of gallons

1980 '85 '90 '95 2000 '05

2005: 3.9 billion

CORN-BASED

Primary ingredient: Corn kernels

PROCESS

Grinding

Corn kernels are ground into flour, and water is added to form a "mash."

Unlocking sugars

Common enzymes are added to the mash to convert starches into dextrose, a simple sugar.

Cooking

The mash is cooked to reduce bacteria levels and then cooled.

Fermenting

Yeast is added to the mash in fermenters. After 40-50 hours, the sugar in the mash ferments into ethanol.

Distilling

Ethanol is separated from the rest of the mash and concentrated.

Blending

Ethanol is blended with about 5 percent of a denaturant to make it undrinkable and thus not subject to a liquor tax.

Finished ethanol for storage

Pros

- Starch in kernels contains easily accessible sugars to be converted to energy.

Cons

- Expanded use could lead to an increase in food prices and the need for much more cropland.

- Growing more corn and processing it into ethanol would require additional use of fossil fuels.

CELLULOSIC

Primary ingredient: Corn stalks, switch grass, wood chips, organic waste.

HOW CELLULOSIC PROCESS DIFFERS:

(Switch grass illustrated)

Unlocking sugars

Because its sugars are more difficult to extract, extensive pretreatment with acid or steam is required. Special enzymes also are used due to the stronger composition of the biomass.

Fermenting

Genetically modified yeast or another fermenting agent is required.

Pros

- Made from cheap, abundant materials.

- Expanded use of cellulosic ethanol would have no effect on the food supply.

- Production creates far fewer greenhouse gases than corn-based ethanol, in part because one of its byproducts, lignin, can be used to help power the plant.

Cons

- Requires an expensive process that is unproven on a commercial scale.

- The cost to build a biorefinery is $2.50 to $4 per gallon of production capacity compared with $1 to $1.50 for corn-based ethanol.

Sources: Renewable Fuels Association, Tribune reporting

Chicago Tribune/Adam Zoll and Phil Geib


Copyright © 2006, Chicago Tribune

[bossi1]

October 17, 2006 09:58:00 AM
ETMarket Report -- Short Stories

Dyadic International, Inc.(DIL)

Dyadic Intl Cantor Fitzgerald initiates Buy. Target $8.5.

Cantor Fitzgerald initiates DIL with a Buy and an $8.50 tgt saying they expect Dyadic to become a leader in providing enabling enzymes to convert sugars into sustainable biofuels and industrial enzymes, a market opportunity of $4.2 bln in 2010 with a potential market of $14 bln for ethanol alone, supported by macro geopolitical, environmental and economic drivers. Firm says Dyadic\'s proprietary C1 integrated discovery-through-commercial manufacturing technology could enable the cost-effectiveness required to maintain a long-term competitive position in cellulosic bioethanol. C1 is a next-generation technology platform and the firm expects Dyadic to widely leverage C1 to discover and produce enzymes for high value growth markets: biofuels, industrial enzymes and biopharmaceuticals -- both monoclonal antibodies and therapeutic proteins, a $30 bln biomanufacturing opportunity in 2010.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.

http://news.moneycentral.msn.com/provider/providerarticle.as…

[bossi1]

[bossi1]

US Börsenaufsicht (SEC) zu DYADIC

http://www.sec.gov/cgi-bin/srch-edgar?text=dyadic&first=1994…

[bossi1]

Bioethanol der 2 Generation aus Biomasse mit Enzymen
Nur so kann man preiswerte Rohstoffe nutzen...

[bossi1]

Zusammenfassung zu Dyadic International (Yahoo)

Dyadic International, Inc. engages in the development and distribution of specialty enzymes and related products to the textile, food and feed, starch, pulp and paper, and other industries in the United States, Hong Kong, Poland, and the Netherlands. It focuses on functional proteomics through the discovery, development, and manufacturing of novel products, including enzymes and proteins, derived from the genes of complex living organisms. The company develops enzymes and other biological products for various industrial and commercial applications; and human therapeutic proteins used by pharmaceutical and biotechnology companies in pre-clinical and clinical drug development applications. Dyadic International was founded in 2002 and is headquartered in Jupiter, Florida.

Yahoo finance USA
http://finance.yahoo.com/q/pr?s=DIL

Yahoo! Message Board zu DYADIC
http://messages.finance.yahoo.com/mb/DIL

[bossi1]

October 28, 2006
Abengoa teams up with Dyadic on cellulosic ethanol. Here's some big news which could help speed up the commercial production of 'cellulosic ethanol,' considered by many to be the key to the future of biofuels.

...Big News, auch speed für die Aktie??

Abengoa, the Spanish company which is one of the world leaders in ethanol, has invested $10 million in the Florida company, Dyadic International, in its quest to bring cellulosic ethanol to market.

It's a huge step for Dyadic, a relatively small Jupiter-based company, that has been making a name for itself through its pioneeering fungal enzyme research (Click here to read my story in the St Petersburg Times, and another recent story by Michael Oneal in the Chicago Tribune.)

"We believe this validates the work we have been doing for a decade to make cellulosic ethanol a commercial reality," says Dyadic's CEO, Mark Emalfarb.

Abengoa claims to be the world's second largest ethanol producer with $3 billion in revenues. It has major investment in the corn-for-ethanol industry in the United States. Abengoa is widely considered to be at the forefront of the industry's efforts to boost the production efficiency of ethanol (and thereby its cost) by using plant waste (fibrous stalk material) which is currently discarded as residue in the production of ethanol.
The technology already exists to convert the plant waste into ethanol, by extracting the cellulose. The challenge lies in pre-treatment of the tougher, fibrous waste material into a manageable form for the extraction of the cellulose. Until now this energy intensive phase in the process has been cost prohibitive.

Several other companies are working on different methods to breakdown the fibrous plant matter, including Iogen and Cellunol. But Abengoa's size, coupled with Dyadic's proven technology, could prove to be the winning combination.

The deal between Abengoa and Dyadic is a three-year research and development agreement involving a $10 million purchase of Dyadic stock by Abengoa Bioenergy R&D, Inc. Dyadic hopes to use the proceeds to develop a cost-effective enzyme production system using its patented C1 enzyme technology for commercial application in Abengoa's cellulosic ethanol production process.

A press release announcing the deal includes this ringing endorsement of Dyadic's scientific work. "We recognized that Dyadic's enzyme technology, especially in the field of cellulosic ethanol, is state-of-the-art," said Gerson Santos-Leon, R&D Director of Abengoa Bioenergy. "Abengoa Bioenergy is looking forward to working with Dyadic in the development of large-scale enzyme production systems and manufacturing processes for use in the production of abundant low cost fermentable sugars from biomass, with initial focus on cellulosic ethanol production."

Emalfarb described the deal as a win-win for both partners. "We have brought the academic effort close to commercialization," he told me in a phone conversation today. He described it as a two-pronged attack, designed to improve the technology while at the same time applying it to the specific type of plant materials Abengoa believes are best suited to cellulosic ethanol production.
"They (Abengoa) are interested in helping the core technology get better and applying it to make the enzymes they need to get their plant material to produce ethanol," Emlafrab said. "They find a partner to get to where they want to go. That's great for them, and its great for us."

The deal is non-exclusive meaning that Dyadic is also free to seek other investors. The deal with Abengoa will certainly make Dyadic a lot more attractive to others interested in cellulosic ethanol technology. Emalfarb says several companies have shown interest, including big oil and agricultural firms. "This should be a catalyst, just as enzymes are, to other deals. The door is wide open."

Dyadic has been involved for a number of years in the research and manufacture of biological products using fungal strains to produce enzymes and other biomaterials. Its efforts have focused on a system for protein production based on the patented 'Chrysosporium lucknowense' fungus, known as C1. Besides ethanol, Dyadic's C1 technology also is being developed to facilitate the discovery and development of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 customers in about 50 countries.

Abengoa Bioenergy, headquartered in St Louis, Missiouri, is one of the five business units of Abengoa, a listed company on the Madrid Stock Exchange and a presence in more than 70 countries.

- David Adams

October 28, 2006 in Ethanol | Permalink

http://blogs.tampabay.com/energy/2006/10/heres_some_big_.htm…

[Lanzalover]

hi hallo!

ich wußte doch, du machst bestimmt einen thread zu dzadic auf!

bist du schon drin?

mhg.

[bossi1]

Antwort auf Beitrag Nr.: 25.016.189 von Lanzalover am 30.10.06 18:58:07

bist du schon drin?

Ich habe bald wieder Zockergeld frei. Als kleine Depotbeimischung mit 8,50 USD Kursziel oder mehr. Ich werde mich aber noch weiter in den US Borads zum Thema umsehen. Der Chart sieht lecker aus. Ich habe Dir in den Ibex35 einen Artikel zu Endesa reingestellt.

Salu2, bossi

[bossi1]

November 09, 2006 04:31 PM Eastern Time
Dyadic Reports 2006 Third Quarter Financial Results

JUPITER, Fla.--(BUSINESS WIRE)--Dyadic International, Inc. (AMEX.DIL), a biotechnology company, today announced financial results for the third quarter ended September 30, 2006, highlighted by a notable increase in sales of the Company's proprietary enzymes to customers in the pulp and paper industry, effective cost management resulting in a strong closing cash balance, and improved gross margin as compared to the third quarter of 2005.

Third Quarter 2006:

Total net sales for the quarter ended September 30, 2006 increased slightly to approximately $4.2 million, as compared to approximately $4.1 million for the quarter ended September 30, 2005.

Third quarter 2006 net sales to the pulp & paper industry increased by 72% versus prior year to approximately $0.9 million, which represented 21% of net sales as compared to 13% of net sales for the third quarter of 2005. Textile industry net sales were approximately $2.4 million for the third quarter of 2006 versus approximately $2.8 million in the third quarter of 2005. As previously reported, the market for enzymes for applications in the textile industry continues to be affected by global pressure on pricing and margins. Sales of enzymes to the animal feed and other markets increased to approximately $0.9 million for this year's third quarter from approximately $0.8 million for the same period of 2005.

Gross margin for the third quarter of 2006 increased to 31% of revenue as compared to 20% for the third quarter of 2005, reflecting the shift in sales from the textile industry to the pulp and paper, animal feed and other higher margin industries.

Net loss for the quarter ended September 30, 2006 decreased to approximately $2.3 million, or $0.10 per share (basic and diluted), as compared to a net loss of approximately $2.5 million, or $0.11 per share (basic and diluted), for the quarter ended September 30, 2005.

At September 30, 2006, cash and cash equivalents were approximately $9.4 million, prior to the closing on November 8, 2006 of the $10 million R&D and stock purchase transaction with Abengoa Bioenergy. Inventories at the end of this year's third quarter were approximately $6.3 million. Working capital at September 30, 2006 amounted to approximately $16.5 million, and shareholders' equity was approximately $17.9 million.

Nine Months 2006:

Net sales for the nine months ended September 30, 2006 were approximately $12 million as compared to approximately $11.9 million for the comparable period last year. Net sales to the pulp & paper industry increased by 63% for the nine months ended September 30, 2006 over those in the same period last year, and totaled approximately $2.1 million. Textile industry net sales were approximately $7.8 million for the first nine months of 2006 versus approximately $8.6 million for the same period last year. Sales of enzymes to the animal feed and other markets increased to approximately $2.1 million for the first nine months of 2006 from approximately $1.9 million for the same period of 2005.

Gross margin for the nine months ended September 30, 2006 increased to 27% of revenue as compared to 20% for the first nine months of 2005. This increase was primarily the result of a 32% increase in net sales of higher-margin products to industries such as pulp & paper, animal feed and others to a total of approximately $4.2 million for this year's first nine months, as compared to approximately $3.2 million for the comparable period last year.

Net loss for the nine months ended September 30, 2006, was approximately $7.7 million, or $0.33 per share (basic and diluted), as compared to net loss of approximately $7.9 million, or $0.36 per share (basic and diluted), for the nine months ended September 30, 2005.

"We made important strides in the development of our core C1 and other enabling technologies for our enzyme, biorefinery and bioscience initiatives, while effectively managing our cash position," said President and CEO Mark Emalfarb. Cash at September 30, 2006, was approximately $9.4 million, prior to the closing on November 8, 2006 of the $10 million R&D and stock purchase transaction with Abengoa Bioenergy Company, a major global ethanol producer and a leader in the production of ethanol from both corn and cellulose feedstocks.

"In addition to significantly enhancing our cash position, we believe our partnership with Abengoa will help us accelerate the development of our proprietary C1 biofactory and other technologies for large-scale production of fermentable sugars which may be used for the production of ethanol, other biofuels, polymers and other chemicals from renewable biomass, thereby transitioning our petroleum-based economy to one based on agricultural residues and energy crops," Emalfarb said.

C1 Host Technology Development Progress Update

Dr. Glenn Nedwin, Dyadic's Chief Science Officer and President of the Biosciences Business, commented, "Dyadic recently was granted an important U.S. patent which we believe protects our novel technology for robotic screening in filamentous fungi using our C1 platform, further strengthening the Company’s intellectual property position. With broad claims covering C1 (Chrysosporium lucknowense) and a number of other industrially relevant fungi, including Trichoderma and Aspergillus, we believe the patent also validates Dyadic's 'one stop shop' model where gene discovery and improvement, gene expression, and product manufacturing can all be performed in the same host organism. This provides Dyadic with a unique capability to improve the odds of identifying potentially useful proteins and to screen for gene variants for improving functional properties of target proteins, thereby shortening R&D development timelines, reducing development costs, and increasing the probability of successfully bringing products to the market."

Dr. Nedwin continued, "We have also had success in further developing our C1 fungal biofactory for the production of human antibodies and other high-value therapeutic proteins. We have successfully expressed a fully functional, bioactive, stable monoclonal antibody in our low protease C1 strain. Due to its expected low cost of manufacturing as compared to mammalian cells and its ability to produce human proteins, we believe our C1 host may become a significant alternative production host for the pharmaceutical industry.

"Other recent C1 technology developments include the identification of a number of novel enzymes which may be important for low-cost production of fermentable sugars, initially targeted towards cellulosic ethanol production, and the ability to over-express multiple genes in C1. We also are moving forward in our collaboration with The Scripps Research Institute to further annotate the C1 genome, which will yield a comprehensive genetic and biochemical blueprint. We believe that these tools may allow us to identify additional commercial enzyme product leads, including improved cellulases and hemicellulases for use in textile, pulp and paper, food and animal feed applications, the production of ethanol from biomass, and the identification and production of high-value therapeutic proteins. We expect that these improvements in our core C1 and related technologies will enable C1 to produce a wider variety of proteins at higher yields and at lower cost."

About Dyadic

Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States of America, Hong Kong and mainland China, Poland and The Netherlands, is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.

http://home.businesswire.com/portal/site/google/index.jsp?nd…

[bossi1]

Dyadic to sell $13 million in shares
By staff report
November 21, 2006

Dyadic International, Inc. (AMEX: DIL), a biotechnology company, intends to expand its technology development program through the private placement of $13 million in common stocks. Institutional investors will be able to buy 2.78 million shares of common stock at a price of $4.68 per share. "The net proceeds are anticipated to help us strengthen the product pipeline for our Enzyme business, accelerate the commercial launch of new products in pulp & paper, animal feed and other areas, and expand R&D infrastructure as well as our sales and marketing efforts," commented Mark Emalfarb, Dyadic's President and CEO.

http://www1.tcpalm.com/tcp/business/article/0,2541,TCP_998_5…

[bossi1]

Abengoa Bioenergy R&D - R&D Investment Strategy
Significant investment in enzyme technology to produce ethanol from cellulosic biomass ...aus den letzten Monaten



Abengoa Bioenergy R&D, Inc. (ABRD) has made a significant strategic investment in Dyadic International, Inc. (Dyadic), a biotechnology company which is emerging in the bioethanol industry. By funding a three year research and development (R&D) program to be performed by Dyadic’s R&D subsidiary, this investment is targeted to result in customized enzyme technologies for ABRD to incorporate in its proprietary biomass-to-ethanol process. ABRD also received specific number of Dyadic shares that are traded on the American Stock Exchange.
The R&D agreement has as its objective the development of a cost-effective enzyme production system for commercial application in ABRD’s proprietary cellulosic ethanol production process. The R&D agreement calls upon Dyadic to use its proprietary technologies to develop one or more enzyme mixture manufacturing systems customized to ABRD’s proprietary biomass substrates. The R&D agreement contemplates that Dyadic will perform both foundational research of general application to the cellulosic ethanol field and specific applications research for the achievement of the goals of the program for ABRD.

The participants are enthusiastic about creating this new working relationship and optimistic about the potential returns for each company as well as for the biofuels industry:
«Abengoa Bioenergy is considered to be the second largest ethanol producer in the world and a leader in the fields of both corn-derived and cellulose-derived ethanol production. We are extremely pleased to partner with Abengoa Bioenergy to leverage Dyadic’s patented C1 platform enzyme technology to enable commercial development of biomass derived ethanol,» said Glenn E. Nedwin, Ph.D., Chief Science Officer for Dyadic. Dyadic’s President and CEO, Mark Emalfarb, further added that «Abengoa Bioenergy is a visionary company and an important first partner for Dyadic for its Biorefineries Business. Additional partners will stand to benefit not only from access to Dyadic’s technologies specific to their area of interest but also from the core technology development program that is fundamental to efficient production of ethanol, other biofuels, polymers and other chemicals from biomass, thereby reducing our dependence on foreign oil.»
ABRD believes that Dyadic’s enzyme technology, especially in the field of cellulosic ethanol, is state-of-the-art, and has entered into this transaction in order to work with Dyadic in the development of large-scale enzyme production systems and manufacturing processes for use in the production of abundant low cost fermentable sugars from biomass, with initial focus on cellulosic ethanol production. This investment and the R&D collaboration with Dyadic represent a key building block in the Abengoa Bioenergy Biomass Program, particularly in the area of specialized enzymes.

[bossi1]

The ethanol of the future may not come from the cornfield...


Wednesday, February 28, 2007
By Steve Tarter

PEORIA - The growth of ethanol is widely touted as the reason corn prices are up around the country and why more corn will be planted in Illinois this year - as much as 15 percent more than last year.


Hefty federal goals are in place calling for 20 percent of the nation's gasoline to be displaced by alternative energy sources by 2019.

But the ethanol of the future may not come from the cornfield. It may be derived from switchgrass, wood chips or even garbage.

"We don't view corn to ethanol as the most viable strategy," said Sasha Bondar, spokesman for Jupiter, Fla.-based Dyadic International Inc., a firm that develops enzymes to accelerate the process of breaking down plant material so it can be converted to fuel.

Dyadic has been working on a process with the Iowa Corn Promotion Board and the U.S. Department of Energy as well as collaborating with Abengoa Bioenergy, a Spanish firm, on pilot plants in Spain and Nebraska, he said.

The race to break down plants other than corn in an economically feasible manner is the challenge of the day, said Bondar. "It's a competitive race and there are quite significant rewards to the company that makes it viable," he said.

"We think we're one of only three or four companies that can get there," said Bondar, adding the effort also involves collaboration to be successful.

The idea of cellulosic ethanol isn't new. Peoria's Ag Lab worked on the concept during World War II, said Bruce Dien, a chemical engineer at the lab.

What drove research then was the possibility of making rubber for the war effort, he said. "After WWII, interest in making ethanol died down. During the 70s' oil crisis, interest grew again - this time in using ethanol for fuel. About 10 years ago, that interest was renewed," said Dien.

The Peoria research facility, the largest of four U.S. Department of Agriculture laboratories in the country, is responsible for several breakthroughs on the cellulosic ethanol front, Dien said.

"In the early 1980s, we came up with ways to allow for the fermentation of plant material," he said.

Ethanol can be made from various plant materials now, he said. The key is to be able to do it as cheaply and easily as possible, said Dien.

Ethanol producers like Pekin's Aventine Renewable Energy Inc. are also looking at new processes. "We've been working with Purdue University and enzyme companies on coming up with an economical way to break that corn fiber down," said Aventine CEO Ron Miller.

Being able to use more of the corn plant could yield as much as 15 percent more ethanol at the company's wet mill facility, he said.

"We look at cellulosic ethanol as a bolt-on facility," said Miller, indicating that once the process is refined, a cellulosic plant could be set up next to the main Aventine plant.

© 2007 PEORIA JOURNAL STAR, INC.

[gbra]

Antwort auf Beitrag Nr.: 28.230.412 von bossi1 am 11.03.07 15:08:28

hola bossi!

nachdem ich bei abengoa ausgestoppt wurde und den wiedereinstieg verpasst habe, bin ich auf der suche nach -langfristig == >3jahre - attraktiven investments.
dyadic ist in einem sehr interessanten bereich tätig, aber ich kann die zukünftigen erträge schlecht einschätzen. bei der momentanen bewertung ist doch schon ein wenig goodwill eingepreist...
dafür sieht es charttechnisch spannend aus. abnehmende volatilität und nach unten relativ gut abgesichert.
wie sehen denn deine erwartungen aus?

saludos !

[bossi1]

Antwort auf Beitrag Nr.: 28.253.900 von gbra am 12.03.07 14:28:14

wie sehen denn deine erwartungen aus?



Hi gbra,
DYADIC würde ich als Depot Beimischung sehen. Es gibt wenig Infos zu dem Nebenwert aus der AMEX und ich habe ihn mir wegen ABG angesehen. In den ersten 9 Monaten 2006 steigerte sich der Umsatz nur leicht, der Verlust lag noch bei 0,11 USD/Aktie für diesen Zeitraum. Für Abengoa und den Partner DYADIC stehen 76 Mill.USD zweckgebundene Fördergelder bereit für das Projekt in Colwich, Kansas mit 11,4 Mill. gal. Das Werk soll Ende 2008 in Betrieb gehen. Die gleiche Technik soll in Salamanca zum Einsatz kommen mit ca. 5 Mill. ltr./Jahr. Im Moment ist Phantasie im Wert, der Chart sieht gut aus, nur für weitere Kursanstiege müssen auch vermarktbare Erfolge und Umsätze dazu kommen. Sehr interessant finde ich die möglichen Rohstoffe, wo neben Stroh und Biomasse Abfällen (Mais), auch Swichgrass (in den USA), auch ungenutzte Zuckerrohrabfälle (Indien, China Brasilien) möglich wären, die sonst verbrannt werden. Das wird noch einige Zeit brauchen.

S2, bossi

------------------------

Von ihrer Homepage:

Dyadic International, Inc. is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper and animal feed industries.

[bossi1]

Dyadic: Enzymes Made to Order
By Billy Fisher
March 13, 2007

Mark A. Emalfarb, Chairman and CEO of Dyadic International (NYSE: DIL), has brought the genomics company he founded a long way. He's applying his company's custom enzyme creation technology to serve a diverse array of customers, from ethanol producers to the pulp and paper industry.

Near the end of 2006, Dyadic inked a three-year R&D deal with international ethanol powerhouse Abengoa Bioenergy (OTC BB: ABG.MC). Dyadic hopes to apply its patented C1 platform enzyme technology toward commercial-scale conversion of just about any kind of agricultural biomass -- from corn to cornstalks -- into the fermentable sugars required to create ethanol. "Our goal is to achieve this in a cost-effective manner," Emalfarb said in a recent Fool interview, "and I think we will get there sooner than people believe."

In a demonstration to Emalfarb's commitment to his company's future, the CEO recently shelled out the bulk of a revolving note to Dyadic to help the company to strengthen its operations. "We didn't want to dilute the ownership of our existing shareholders," he said of the unorthodox financing move.

Fools who don't own shares of Dyadic should be aware of the company's risks. It's still incurring losses as it strives to commercialize its enzyme technology. In its most recently filed 10-Q, the company reported a net loss of $0.33 per share for the nine months ended Sept. 30, 2006. Dyadic also predicted substantial future capital requirements in the same report.

Dyadic's diversification helps distinguish the company from ethanol-related rivals like VeraSun Energy (NYSE: VSE) or U.S. BioEnergy (Nasdaq: USBE). "We are not a pure ethanol play," Emalfarb said. The company's Q3 net sales to the pulp and paper industry increased by 72% year over year. They now represent 21% of Dyadic's net sales, versus only 13% in the prior-year quarter. While Dyadic's R&D forges ahead in ethanol, the company's successful diversification should provide an added cushion of cash.

http://www.fool.com/investing/general/2007/03/13/dyadic-enzy…

[bossi1]

Dyadic Reports 2006 Financial Results
Apr 2 2007, 4:31 PM EST
Business Wire


Dyadic International, Inc. (AMEX.DIL), a global biotechnology company that uses its patented and proprietary technologies (the "Dyadic Platform Technology") to conduct research and development activities for the discovery, development and manufacture of products and enabling solutions to the bioenergy, industrial enzyme and pharmaceutical industries, today announced financial results for the year ended December 31, 2006.

Financial Results

Total net sales for the year ended December 31, 2006, were approximately $15.4 million as compared to approximately $15.9 million for 2005. The decline in sales primarily reflected lower prices in the textile industry, which represented 65% of total sales for 2006 as compared to 72% of total sales for 2005. This decline was partially offset by an increase in higher-margin sales to customers in the pulp & paper, animal feed and other industries, which represented 35% of total sales for 2006 as compared to 28% of total sales for 2005.

Gross margin for 2006 increased to approximately $4 million, or 26% of net sales, as compared to approximately $3 million, or 19% of net sales, for 2005. This increase primarily reflected the Company's directed efforts to shift sales from the textile to the pulp and paper, animal feed and other higher-margin industries.

2006 net sales to the pulp & paper industry increased by 41% versus prior year to approximately $2.6 million from approximately $1.9 million, which represented 17% of net sales as compared to 12% of net sales for 2005. Net sales to the animal feed industry increased by 31% to approximately $1.4 million for 2006 from approximately $1.0 million for 2005, which represented 9% of net sales versus 7% for the prior year.

Net loss for 2006 was approximately $10.9 million, or $0.45 per share (basic and diluted), as compared to a net loss of approximately $10.5 million, or $0.48 per share (basic and diluted), for 2005.

Balance Sheet Highlights

At December 31, 2006, Dyadic reported working capital of approximately $36.7 million, including cash and cash equivalents of $31.1 million. This compares to working capital at December 31, 2005, of $16.6 million, including cash and cash equivalents of $12.1 million. Stockholders' equity at December 31, 2006, was $28.2 million, as compared to $15.3 million at December 31, 2005.


President and CEO Mark Emalfarb said, "We made substantial and
important progress on all fronts during 2006:

-- "We strengthened our executive management team and global
infrastructure, as highlighted by the hiring of Dr. Glenn Nedwin as
our Chief Science Officer, President of our BioPharma Business and
member of our board of directors;

-- "We entered into a new scientific collaboration with The Scripps
Research Institute to annotate the genome of our patented C1
fungus. We expect this project to help us enhance the Company's
leadership in the development of cost-effective enzyme mixtures and
related processing and manufacturing technologies for use in the
production of cellulosic ethanol and biotherapeutic proteins;

-- "We entered into a non-exclusive research and development and
commercialization agreement with Abengoa Bioenergy, R&D, Inc., a
subsidiary of Abengoa, S.A., the world's second largest ethanol
producer. Our objective is to develop cost-effective enzyme
mixtures and related processing and manufacturing technologies for
commercial application in Abengoa's cellulosic ethanol production
process. As part of this agreement, Abengoa Bioenergy paid $10
million to Dyadic to fund our research and development efforts and
was issued approximately 2.1 million shares of our common stock.

-- "Dyadic also joined one of Europe's leading producers of
bioethanol, Royal Nedalco, and other partners in R&D projects
funded by the Netherlands government to develop technologies to
produce ethanol from sugar beet pulp and wheat bran;

-- "We made substantial progress in our efforts to enhance our
knowledge and increase the capabilities of the Dyadic Platform
Technology, including our expression systems:

-- We developed the capability to over-express multi-enzyme
monocomponents in the same production host, leading to
lower-cost enzymes for cellulosic ethanol, and promising
production models for commercially important monoclonal
antibodies for human therapeutics;

-- We expressed stable, biologically active full-length
monoclonal antibodies in gram-per-liter quantities;

-- "We strengthened our balance sheet with the net proceeds received
from the closing of a $13 million private placement with several
institutional investors. Together with the proceeds from purchase
of our common stock by Abengoa Bioenergy, this increased Dyadic's
cash position to more than $31 million at December 31, 2006."

Mr. Emalfarb continued, "Building on these accomplishments, we believe that we have positioned Dyadic to accelerate our efforts on all fronts in 2007 and beyond. Among our primary goals for 2007, we hope to enter into additional strategic collaborations related to cellulosic ethanol and to further improve the efficiency of cost-effective enzyme mixtures and related processing and manufacturing technologies for applications in this growing market. We also expect our C1 annotation project with Scripps and other initiatives to yield a growing number of genes to facilitate the potential development of new products for applications in all of our target markets. Our financial resources, together with the advances we have made in our R&D initiatives in bioenergy and biopharmaceuticals, and anticipated continued growth in sales of our proprietary enzyme products for the pulp & paper and animal feed industries, position Dyadic for further progress in 2007 and beyond."

Glenn Nedwin, Chief Science Officer, added, "Our R&D efforts are focused on providing a route to inexpensive sugar production from agricultural biomass, a crucial step in the production of cellulosic ethanol. During 2006, we developed enzyme mixtures that successfully converted over 40 different biomass feedstocks into sugars and at higher yields than previously achieved.

"Another significant development this past year was the award of a broad U.S. patent that protects Dyadic's technology for high-throughput robotic screening (HTS) in filamentous fungi using our proprietary Dyadic Platform Technology. The C1 HTS Technology is expected to permit rapid screening for the discovery of genes and the proteins and enzymes they produce, as well as identification of improved protein variants resulting from modifications to these genes. We believe this patent strengthens Dyadic's 'one stop shop' model where gene discovery and improvement, gene expression, and product manufacturing in quantities from 1 ml to 150,000 liters can all be performed in the same host organism.

"In addition to its applications in our Bioenergy Business, our HTS technology also may improve the odds of identifying potentially useful human antibodies and other classes of high-value human therapeutic proteins, shorten R&D development timelines and reduce development costs."

About Dyadic

Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States, Hong Kong and mainland China, Poland and The Netherlands, is a global biotechnology company that uses its patented and proprietary technologies (the "Dyadic Platform Technology") to conduct research and development activities for the discovery, development, and manufacture of products and enabling solutions to the bioenergy, industrial enzyme and pharmaceutical industries. Dyadic's enabling solutions include novel, cost-efficient production strains, enzyme mixes and related fermentation processes currently in development to produce abundant, low-cost fermentable sugars from agricultural residues and energy crops, which can then be used in the production of cellulosic ethanol as well as other products currently derived from petroleum. Dyadic also develops low-cost production hosts for therapeutic protein production for the biopharmaceutical industry, and manufactures more than 55 liquid and dry enzyme and other biological products for more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, food, starch, alcohol, and fuel ethanol industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2006, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.


Dyadic International, Inc.
Consolidated Balance Sheet
December 31, 2006

Assets
Current assets:
Cash and cash equivalents $31,072,824
Accounts receivable, net of allowance for
uncollectible accounts of $240,490 2,788,588
Inventory 6,039,080
Prepaid expenses and other current assets 1,170,528
------------
Total current assets 41,071,020
------------

Fixed assets, net 1,813,468
Intangible assets, net 96,047
Goodwill 1,808,458
Other assets 348,387
------------
Total assets $45,137,380
============

Liabilities and stockholders' equity
Current liabilities:
Accounts payable $2,238,585
Accrued expenses 1,905,382
Accrued interest payable to stockholders 48,897
Short term notes payable 191,125
Income taxes payable 26,730
------------
Total current liabilities 4,410,719
------------

Long-term liabilities:
Note payable to stockholder 2,378,832
Other liabilities 160,808
Deferred research and development obligation 9,997,863
------------
Total long-term liabilities 12,537,603
------------
Total liabilities 16,948,222
------------

Stockholders' equity:
Preferred stock, $.0001 par value:
Authorized shares - 5,000,000; none issued and
outstanding --
Common stock, $.001 par value:
Authorized shares - 100,000,000; issued and
outstanding - 29,792,992 29,793
Additional paid-in capital 73,261,774
Notes receivable from exercise of stock options (212,500)
Accumulated deficit (44,889,909)
------------
Total stockholders' equity 28,189,158
------------
Total liabilities and stockholders' equity $45,137,380
============

Dyadic International, Inc.
Consolidated Statements of Operations

Year Ended December 31
2006 2005
---------------------------

Net sales $15,383,754 $15,882,969

Cost of goods sold (includes non-cash
share-based compensation of approximately
$32,000 for 2006) 11,345,144 12,856,607
---------------------------
Gross profit 4,038,610 3,026,362
---------------------------

Operating Expenses:
Research and development (includes
non-cash share-based compensation
of approximately $89,000 and
$19,000 for 2006 and 2005,
respectively) 4,236,448 4,655,486
Sales and marketing (includes non-
cash share-based compensation of
approximately $75,000 for 2006) 3,417,013 2,808,937
General and administrative (includes
non-cash share-based compensation
of approximately $592,000 and
$58,000 for 2006 and 2005,
respectively) 7,149,005 5,564,619
Foreign currency exchange gains, net (28,704) (16,785)
---------------------------
Total operating expenses 14,773,762 13,012,257
---------------------------

Loss from operations (10,735,152) (9,985,895)
---------------------------

Other income (expense):
Interest expense (594,163) (710,537)
Investment income 504,894 249,280
Minority interest (13,355) (4,725)
Other income, net 18,696 1,535
---------------------------
Total other expense (83,928) (464,447)
---------------------------

Loss before income taxes (10,819,080) (10,450,342)

Provision for income taxes 63,112 64,228
---------------------------
Net loss $(10,882,192) $(10,514,570)
===========================

Net loss per common share:
Basic $(0.45) $(0.48)
===========================
Diluted $(0.45) $(0.48)
===========================
Weighted average shares and equivalent
shares used in calculating net loss per
share:
Basic 24,419,097 22,132,158
===========================
Diluted 24,419,097 22,132,158
===========================

[lvb28]

Antwort auf Beitrag Nr.: 28.631.787 von bossi1 am 02.04.07 23:57:08

Abengoa ha obtenido un contrato en Marruecos para construir una central termo-solar por un total 469Mn€ (de los cuales 43Mn€ provienen del Banco Mundial). Abengoa gestionará la central en los cinco años.

este proyecto no es realmente una planta termosolar, plantsino una a de ciclo combinado de 450MW de potencia a la que va a haber anexa un campo termosolar de 20MW.

este contrato supondría unos 56Mn€ en términos de EBITDA, aunque el comunicado de la compañía no aclara si este proyecto será 100% de Abengoa o lo ejecutará con la ayuda de un socio local

no nos acaba de cuadrar la inversión anunciada: usando coste de inversión en España, el MW de ciclo combinado cuesta aproximadamente 0,5Mn€ y el de termosolar unos 4,5Mn€.

Segun estos datos la inversión de la planta y el campo termosolar obtendremos mas o menso 315Mn€.

Me queda ninguna otra solucion como ponerme en contacto
para aclarar estas dudas.

Cao

[bossi1]

Antwort auf Beitrag Nr.: 30.103.225 von lvb28 am 21.06.07 22:26:40

Hola lvb28,

mira abajo en mi foro "solar" el articulo 174,178 & 178 de Abengoa. ABG empeza en Alegeria en el mes julio las obras de otro ciclo combinado (Hybrid) de 130 MW con 25 MW potencia solar. Es un proyecto de ~315 Mn€ participada con otra compania local. Pienso que estan bien los datos del proyecto de Marruecos.

http://www.wallstreet-online.de/dyn/community/thread.html?th…

S2, bossi

PD: Te he visto en foro de Petrobas

[lvb28]

Antwort auf Beitrag Nr.: 30.104.981 von bossi1 am 21.06.07 23:54:39

gracias, voy a mirar a tiro
tu ves yo vivo

y te acompano a ti y tus amigos mas passivo

(Te imagina vecinos de casa te roban en tu subterrano

cerrado todos tus libros, tus recuerdos,
todos tus programas y bibliotheca de programacion
tus cartas documentos etc y tus - vecinos de casa
y lo echan en la basura y no puedes hacer nada
absolutamente nada porque no lo vi con propios ojos

Y aunque la administracion de la casa me dio su permiso de que
puede poner mis cosas por 14 dias en el subtrerano cerrado
y ahora ellos dicen que no saben y rechazan la responsabilidad
y en la consecuencia perdio todo mi estudio

Puedes imgarinarte un poco como me siento
por eso soy aun como narcotisado
lo siento
LVB


(

[[KERN]Codex]

[bossi1]

Antwort auf Beitrag Nr.: 30.140.431 von lvb28 am 22.06.07 08:20:20

...lo siento mucho que te ha pasado. ¿Has recuperado algo? S2, bossi


Dyadic's Amex Listing Will Be Continued Pursuant To An Extension

JUPITER, Fla.--(BUSINESS WIRE)--Jul 9, 2007 - Dyadic International, Inc. (AMEX.DIL) announced today that it has received notice from The American Stock Exchange (the "Amex") that its Amex listing is being continued pursuant to an extension.

On May 21, 2007, the Company announced that on May 17, 2007, it had received notice from the Amex indicating that the Company is currently in violation of the Amex's continued listing standards specified in Sections 134 and 1101 of the Amex Company Guide because the Company had yet to file with the Securities and Exchange Commission ("SEC") its Form 10-QSB for the quarter ended March 31, 2007. The Amex's notice further indicated that the Company had to submit a plan to the Amex by June 18, 2007, advising the Amex on action it has taken, or will take, that will enable the Company to regain compliance with these continued listing standards by no later than November 16, 2007.

On June 18, 2007, the Company submitted a plan of compliance to the Amex. The Amex has completed its review of the plan and has determined that, in accordance with Section 1009 of the Amex Company Guide, the plan makes a reasonable demonstration of the Company's ability to regain compliance with the continued listing standards by the end of the plan period, which has been determined to be no later than November 16, 2007.

The Amex has agreed to continue the Company's listing conditioned upon, among other things, the Company demonstrating progress consistent with the plan prior to the targeted completion date of November 16, 2007. However, the Amex, consistent with its obligations and responsibilities as a self-regulatory organization, may initiate immediate delisting proceedings against the Company as appropriate in the public interest during the plan period despite its conditional continued listing.

The Company will not be deemed to have regained compliance with the Amex continued listing standards, and trading in the Company's common stock will not resume on the Amex, until the Company is current with the filing of its SEC quarterly reports and other SEC periodic reports.

At the end of the plan period, November 16, 2007, the Company must be in compliance with all of the Amex continued listing standards, including being current with the above SEC filings. Failure to regain compliance by November 16, 2007, will likely result in the Amex initiating delisting proceedings against the Company pursuant to Section 1009 of the Company Guide.

[bossi1]

Biofuels News
July 10, 2007
Big business bets on 'bio-refineries' for nation's fuel needs

CAMBRIDGE, Mass. - Innovation in biotech: It's not just about drug development anymore.
As the world gets hungrier for alternative fuels, industrial energy giants are scrambling to form partnerships with niche biotech companies. The race is on to create bioengineered enzymes that are at the heart of cost-effective ways of turning corn, sugar and even wood chips into a gasoline substitute called cellulosic ethanol.

Already, the field has attracted players representing Big Chemical (DuPont), Big Oil (Royal Dutch Shell) and Big Agriculture (Syngenta). Each of them has aligned with small companies like Verenium Corp., Codexis Inc. and Novozymes A/S catering to the growing market for "enzyme cocktails" that can produce ethanol faster and cheaper.

"We think the ethanol revolution is taking place here and it's here to stay," said Charles Holliday Jr., DuPont's chairman and chief executive.

In turn, groups like DuPont have linked up with companies specialized in building alternative-fuel refineries, some of which also make enzymes.

According to a recent study by Burrill & Co., the market for such ethanol- producing enzymes is expected to reach $1.1 billion nearly a decade from now vs. about $100 million in 2007.

By Holliday's reckoning, cellulosic ethanol would yield 30% more per acre over traditional ethanol production because it's based on using whole plants, not just their grains.

Besides the nation's push to wean Americans off of foreign oil, the quest for cellulosic ethanol seeks to address concerns that the U.S. can't grow enough corn to produce enough traditional, corn-based ethanol to meet demand without eating into the food supply.

Most ethanol is produced from corn kernels, using a process akin to distilling beer and other alcohol from gains.

But replacing even a fraction of our gasoline consumption with any type of ethanol appears daunting.

Americans this year will pump about 145 billion gallons of gasoline into cars, trucks and lawn mowers. Meantime, ethanol sales are on pace to reach 7 billion gallons, according to the Biotechnology Industry Organization, the world's leading biotech trade group.

Aiming to make ethanol "cost-competitive" with gasoline, President Bush has set a goal of producing 35 billion gallons of renewable fuels, which would meet 20% of the nation's gasoline demands, by 2017. To get there, ethanol makers must stop relying on corn alone, experts say.

From white to green

That's why investors in the industry are getting excited about an obscure form of biotechnology known as industrial or "white" biotech. Unlike their cousins who work for drug developers, white biotech companies focus on using living components, such as bio-engineered microbes and enzymes, as agents that speed key industrial processes. In the case of ethanol, they're looking at ways to use enzymes to break down tough plant fibers, liberating the industry from its dependence on corn.

Billed as a next-generation form of alternative fuel, cellulosic ethanol can be derived from a wide range of organic sources known as feedstocks or biomass.

They include agricultural waste or crops grown specifically for fuel, such as sawgrass. In addition, most of a plant could be used, instead of just the easy- to-process grain portion, so an ear of corn's cob, stalk, husk and leaves are all thrown in.

Major corporations that have a hand in agriculture or petroleum-based industries have expressed growing interest in cellulosic fuels, hoping to stake a claim on the biofuel frontier. Royal Dutch Shell PLC (RDSA) , Abengoa SA ( ABGOF) and E.I. du Pont de Nemours and Co. (DD) have joined forces with enzyme makers and traditional ethanol companies to fund research and develop an early generation of bio-refineries.

For all the excitement generated by the innovations, experts caution that the road to cellulosic ethanol has a ways to go.

As Alan Shaw, CEO of enzyme developer Codexis quipped, if the earth had created enzymes that could easily break down cellulose, "Our forests would all be lakes of goo."

The role of industrial biotech companies in the quest for cellulosic ethanol is to grab the evolutionary torch from Mother Nature and create micro-organisms that can produce the living enzymes necessary to break down cellulose into sugars, which are then fermented into alcohol. The ethanol is then mixed, up to 10% of volume, with gasoline.

"In the case of conventional ethanol, you're looking at feedstock sources where the sugars have already been highly concentrated, whereas in cellulosic ethanol, the sugars are less accessible," said Carlos Riva, CEO Verenium Corp. ( VRNM) .

"That's really where the differences in production come in. In cellulosic ethanol, you need to put a lot of effort into breaking down the biomass," Riva added.

Cambridge, Mass.-based Verenium, with a market cap of $245 million, was recently created through the merger of Celunol, an ethanol production company, and enzyme specialists Diversa Corp. It was just awarded a U.S. Energy Department contract, led by the Oak Ridge National Laboratory, to develop new biomass enzymes.

Riva sees Bush's ethanol ambitions as a guide to how huge the market could be.

"This is really about a race to market," said Riva, adding that the goal of 32 billion to 35 billion gallons of ethanol a year, assuming a rate of $2 a gallon, would add up to about a $70 billion market.

"What we're trying to do, with our competitors ... is to try to grab a piece of that," Riva said.

DuPont, the former parent of oil giant Conoco, in getting a piece of the action.

"Fuels is an enormous marketplace," said John Pierce, the company's vice president for biotechnology. "And it's not like two or three companies are going to dominate the marketplace."

Drug industry ties

Perhaps unsurprisingly given the newness of the field, the cellulosic ethanol game has attracted an eclectic roster of players.

Privately-held Codexis, which counts Shell as a client, also makes biological products to aid in industrial and pharmaceutical production. Two other well- known players, Genencor and Novozymes A/S (NVZMY) , are the offspring of major Danish corporations: Genencor is a division of food ingredients specialist Danisco A/S (DNSOF) while Novozymes was spun off of drugmaker Novo-Nordisk A/S ( NVO) .

"What Shell wants us to do is design an industrial process that will work economically today and will compete with oil," said Codexis executive Shaw. His company, he says, "literally designs enzymes from scratch."

Also on the scene is Dyadic International Inc. (DYAD). The company struck a partnership with Spanish technology behemoth Abengoa, whose U.S. biofuels division, Abengoa Bioenergy, recently won an Energy Department grant to build an 11.4 million gallons-a-year ethanol plant in Kansas that will use corn stover, wheat straw, switchgrass and other feedstocks. ...und jetzt werden die Enzyme auch für die Zuckerrohrabfälle bei ihren neuen Werken in Brasilien interessant.

Verenium, meanwhile, wants to be a next-generation fuel company. The industrial biotech group has gone into business DuPont and Syngenta Ag (SYT) , a Swiss agricultural conglomerate.

It already operates one of the world's first cellulosic ethanol plants. The facility in Jennings, La., takes refuse from sugarcane production as its feedstock. It has also licensed its technology to Tokyo-based Marubeni Corp. ( MARUY) for use in a cellulosic plant in Osaka that will base its refinery on wood-construction waste.

According to Riva, Verenium is building a 1.4 million gallon-a-year pilot plant that will be finished this year. Eventually the company wants to set up plants that can produce 25 million gallons a year around the country, with the help of some government guaranteed loans and equity investments from major agricultural companies that would supply the feedstock.

"Our plan is to build a fleet of these plants. I think there's enormous value to be extracted managing them as a fleet," Riva says.

Verenium isn't the only biotech player interested in building bio-refineries.

Two competitors are Ottawa-based Iogen Technologies LLC, which is backed by Shell and Goldman Sachs (GS) , and Cambridge-based Mascoma Corp., both of which are privately-held. Like Verenium, both companies focus on creating enzymes to break down biomass.

Iogen recently won a government award to build an 18 million gallons-a-year bio-refinery in Idaho that will squeeze ethanol out of straw from wheat, barley and rice.

Mascoma, meanwhile, has secured funding from a New York state program to build a test plant near Rochester that would produce ethanol from forestry products such as wood chips. The company recently appointed Bruce Jamerson, former head of VeraSun Energy Corp., as its new CEO.

In addition to federal and state funding, Mascoma says it has partnerships with Genencor, Tamarack Energy Inc. and EU ethanol producer Royal Nedalco. Royal Nedalco is a subsidiary of Dutch sugar producer Royal Cosun.

"What you're increasingly seeing is partners coming together to develop a whole value chain," said Matt Carr, an industrial technology policy expert for the Biotechnology Industry Organization.

"It's an evolving game" said DuPont's Pierce. "All business models are still open."

'All about costs'

A crucial hurdle remains bringing down the costs of the cellulose-munching enzymes, which are generally produced by bioengineered organisms. Ethanol makers generally use "cocktails" made up of more than a dozen enzymes to do the chomping.

Carr notes that enzymes to produce corn-based ethanol now run about 5 cents a gallon, while cellulosic enzymes cost about 20 cents a gallon. However, as the production techniques and efficiency of cellulosic enzymes advance, that cost should continue to fall.

Codexis' Shaw says his company has been working to create "super-enzymes" that would slash costs by dramatically reducing the number of different enzymes needed.

"It's all about costs," says Codexis' Shaw. "Oil companies are only going to be interested when the cost gets below the cost of oil."

Another obstacle is the cost of building first-generation cellulosic ethanol bio-refineries.

As a part of its initiative to make the nation more self-reliant fuel-wise, the federal government has become a keen supporter of fostering cellulosic ethanol production, actively funding several research initiatives.

Last February, Energy Department said it would fund $385 million for the construction of six cellulosic ethanol plants around the nation, with the industry putting up over $800 million. Award recipients included Iogen and Abengoa Bioenergy.

"It's designed to demonstrate the commercial viability of cellulosic ethanol," said BIO President Jim Greenwood, a former congressman, said of the government program. "Eventually you want to get the industry to a point where it can compete head-to-head with gasoline."

Copyright (c) 2007 Dow Jones & Company, Inc.

http://www.checkbiotech.org/green_News_Biofuels.aspx?infoId=15097

[bossi1]

September 18, 2007 9:01 PM PDT
Maker of microbe-inspired jet fuels gets more funding

Posted by Michael Kanellos
Amyris Biotechnologies, which is working on make jet fuels, gasoline and medicines through biologically inspired processes, has raised part of a $70 million funding round that it hopes to complete by the end of the year.

The company also said that it will try to come out with its bio-diesel, bio-gasoline and bio-jet fuels as early as 2010.

Amyris specializes in synthetic biology. It studies metabolic processes in bacteria and other microorganisms and then tries to replicate those processes artificially in labs. One of its first projects was developing a synthetic form of artemisinin, a medicine for malaria that grown naturally in mangrove swamps in China. Growing it artificially will, potentially, expand the supply to cover far more patients.

The company has exploited similar processes to turn sugars and other organic materials into fuel. Amyris grew out of research conducted by UC Berkeley's Jay Keasling.

Competitors include Synthetic Genomics (which includes oil giant BP as an investor), Dyadic, LiveFuels, Solazyme, LS9 and Cambrios Technologies. Some of these companies employ synthetic biology and some use the actual, live microbes to do their dirty work.

Duff Ackerman & Goodrich Ventures (DAG Ventures) led the current round of financing and was joined by existing investors such as Khosla Ventures and Kleiner Perkins Caufield & Byers.

Topics:Green tech
Tags:green, amyris, global warming

http://www.news.com/8301-10784_3-9780955-7.html?tag=nefd.blg…